A Study of LY3002813 in Participants With Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

May 3, 2013

Primary Completion Date

August 24, 2016

Study Completion Date

August 24, 2016

Conditions
Alzheimer Disease
Interventions
BIOLOGICAL

LY3002813-IV

Administered IV

BIOLOGICAL

LY3002813-SC

Administered SC

DRUG

Placebo-IV

Administered IV

Trial Locations (6)

30308

Atlanta Center of Medical Research, Atlanta

32806

Compass Research, Orlando

84106

PRAHealthSciences, Salt Lake City

90806

Collaborative Neuroscience Network - CNS, Long Beach

130-0004

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sumida-Ku

162-0053

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01837641 - A Study of LY3002813 in Participants With Alzheimer's Disease | Biotech Hunter | Biotech Hunter